Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00904488
Other study ID # 08-1292
Secondary ID
Status Terminated
Phase Phase 4
First received May 17, 2009
Last updated February 13, 2018
Start date October 2008
Est. completion date November 14, 2017

Study information

Verified date January 2018
Source University of North Carolina, Chapel Hill
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this prospective, randomized, open-label study is to compare two diuretic strategies in patients with acute decompensated heart failure (ADHF): the addition of an oral thiazide diuretic to intravenous bolus (IVB) loop diuretic will be compared to transition from IVB to continuous infusion (CI) loop diuretic.


Description:

Patients hospitalized for ADHF secondary to fluid overload and who are experiencing an inadequate response to IVB furosemide and require additional diuresis will be enrolled. Patients will be randomized to one of two treatment arms: the addition of oral metolazone to continued IVB furosemide versus transition from IVB to CI furosemide. A suggested algorithm for initial dosing and titration of these two diuretic strategies will be provided. Baseline and daily data collection will include various efficacy and safety endpoints including daily net urine output and weight, patient and physician global assessment scale, length of stay, 30-day death or rehospitalization, vital signs, electrolytes, and renal function. Clinically meaningful efficacy and safety endpoints will be compared.


Recruitment information / eligibility

Status Terminated
Enrollment 11
Est. completion date November 14, 2017
Est. primary completion date May 28, 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Greater than or equal to 18 years of age

2. Hospitalized for acute decompensated heart failure (ADHF) secondary to fluid overload as defined by the presence of at least

- 1 symptom (e.g. dyspnea, orthopnea, paroxysmal nocturnal dyspnea) AND

- 1 sign (e.g. rales on auscultation, > 2+ peripheral or presacral> edema, hepatomegaly, ascites, jugular vein distension > 7 cm, pulmonary vascular congestion on chest radiography)

3. Inadequate response to IV diuretics and requiring additional diuresis as determined by primary medical team

4. Received less than six doses of IV furosemide OR enrolled within 72 hours of hospital admission

5. Anticipated need for intravenous diuretic therapy for at least 48 hours

6. Able to provide informed consent

Exclusion Criteria:

1. Receiving a continuous infusion loop diuretic during current hospital visit

2. Substantial diuretic response to pre-randomization diuretic dosing such that higher doses of diuretic would be contraindicated (based on judgement of patient's primary team)

3. Planned or ongoing intravenous vasoactive therapy (e.g. inotrope, vasodilator) or mechanical support (e.g. intra-aortic balloon pump, ventricular assist device) for ADHF during this hospitalization

4. Planned elective admission for elective placement/revision of a cardiovascular device (e.g. defibrillator, biventricular pacemaker) during this hospitalization or such within the preceding 7 days

5. Systolic blood pressure < 90 mmHg

6. Serum creatinine > 3 mg/dL at baseline or renal replacement therapy including ultrafiltration

7. Serum potassium < 3.5 mEq/L (3.0 - 3.4 mEq/L allowed if supplemental potassium is being administered)

8. Serum magnesium < 1.6 mg/dL (1.4 - 1.5 mg/dL allowed if supplemental magnesium is being administered)

9. Acute coronary syndrome or hemodynamically significant arrhythmias causing worsening HF

10. Severe, uncorrected primary cardiac valvular disease, acute myocarditis, constrictive pericarditis, hypertrophic obstructive cardiomyopathy, restrictive or constrictive cardiomyopathy, complex congenital heart disease

11. Primary pulmonary hypertension with right sided heart failure

12. Use of iodinated radiocontrast material in prior 72 hours or planned within the next 48 hours

13. Enrollment or planned enrollment in another randomized clinical trial during hospitalization

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Addition of oral Metolazone
Addition of oral metolazone 5 mg daily to continued current dose of intravenous bolus furosemide
Furosemide dose escalation
Furosemide dose escalation via either IV bolus (2-2.5 x current dose) or continuous infusion (2-2.5 x current dose administered over previous 24 hours)

Locations

Country Name City State
United States UNC_Chapel Hill Chapel Hill North Carolina

Sponsors (3)

Lead Sponsor Collaborator
University of North Carolina, Chapel Hill University of Illinois at Chicago, Virginia Commonwealth University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Daily Net Fluid Output on Day 2 (24-48 Hours After Randomization) Net fluid output = fluid output during 24-48 hours after randomization - fluid intake during 24-48 hours after randomization. A negative value means that daily fluid intake was less than the daily fluid output. 24-48 hours
Secondary Daily Net Fluid Output on Days 1, 3, and 4 Daily net fluid output = daily fluid output - daily intake. A negative value means that daily fluid intake was less than the daily fluid output. 0-24, 48-72, 72-96 hrs
Secondary Daily Urine Output (mL Urine Out Per mg Furosemide (IV Equivalent) Received) 0-24, 24-48, 48-72, 72-96 hrs
Secondary Daily Weight Baseline (Dry), Baseline, 0-24, 24-48, 48-72, 72-96 hrs
Secondary Patient Global Assessment Scale Scale range: 1-5 Which of the following best describes your overall health state today?
= markedly worse
= worse
= neither better nor worse
= better
= markedly better
Baseline, 24, 48, 72, 96 hrs
Secondary Physician Global Assessment Scale Scale range: 1-5 Which of the following best describes the patient's overall health state today?
= markedly worse
= worse
= neither better nor worse
= better
= markedly better
Baseline, 24, 48, 72, 96 hours
Secondary Need for Additional or Alternative Diuretic (Crossover) or Other Vasoactive Therapy (Study Failure) Patients will be considered a treatment failure if they require additional diuretic (including crossover to the alternative study arm) or require IV vasoactive drug therapy (e.g. vasodilators including nitroglycerin or inotropes) as deemed appropriate/necessary by their medical team. 0-96 hours
Secondary Time to Return to Baseline Weight 0-96 hours
Secondary Length of Hospitalization Assessed till hospital discharge, an average of 1 week (longest 29 days)
Secondary 30-day All-cause Mortality 30 days
Secondary Rehospitalization at 30 Days 30 days
Secondary Unscheduled Heart Failure Visits to Emergency Department or Outpatient Clinic 30 days
Secondary Blood Urea Nitrogen (BUN) Baseline, 24, 48, 72, 96 hours
See also
  Status Clinical Trial Phase
Completed NCT04049045 - Effects of Empagliflozin on Diuresis and Renal Function in Patients With Acute Decompensated Heart Failure Phase 2
Active, not recruiting NCT05100836 - SURPASS Impella 5.5 Study
Recruiting NCT02898181 - Low Level Tragus Stimulation in Acute Decompensated Heart Failure N/A
Completed NCT02823626 - High-dose Aldosterone Antagonist for Acute Decompensated Heart Failure
Completed NCT02248831 - Evaluation of Cardiopulmonary Diseases by Ultrasound N/A
Completed NCT02196038 - A Trial of Rehabilitation Therapy in Older Acute Heart Failure Patients N/A
Completed NCT00693745 - Neutrophil Gelatinase-Associated Lipcalin (NGAL) Evaluation Along With B-Type Natriuretic Peptide in Acutely Decompensated HF N/A
Not yet recruiting NCT04391231 - HEMolysis in a Percutaneous Axial Flow LVAD, Effects of Pentoxifylline in a Randomized Controlled Trial Phase 4
Recruiting NCT05206422 - DORAYA-HF Early Feasibility Study N/A
Recruiting NCT01960218 - Gas Exchange for Predicting Hospital Heart Failure Readmissions N/A
Terminated NCT02620384 - Metolazone As Early Add On Therapy For Acute Decompensated Heart Failure (MELT-HF)--A Single Center Pilot Study. Phase 3
Completed NCT04318093 - Study of the Safety of BMS-986259 in Participants With Post-Acute Decompensated Heart Failure Phase 2
Recruiting NCT06161649 - Mobile Education System to Improve Disease Knowledge, Self-efficacy and Quality of Life in Patients With Heart Failure N/A
Completed NCT02289508 - Role of USCOM in Adult Patients With Heart Failure N/A
Terminated NCT01457053 - Assessment of Coronary Flow Reserve in Heart Failure Patients After Ultrafiltration Versus Diuretics N/A
Completed NCT04877652 - DR REGISTRY: Prospective Observational Study of ADHF Patients With Insufficient Response to Diuretics
Completed NCT03505788 - Acetazolamide in Decompensated Heart Failure With Volume OveRload (ADVOR) Phase 4
Completed NCT03146754 - A Study to Evaluate Lung Ultrasound as a Method to Measure Changes in Extravascular Lung Water Induced by Positional Changes (LUPE) N/A
Not yet recruiting NCT06414759 - Efficacy and Safety of Combination Diuretic Therapy in Patients With Acute Decompensated Heart Failure and Volume Overload Phase 4
Terminated NCT05346653 - The Hemodynamic Effects of SGLT2i in Acute Decompensated Heart Failure Phase 4